Host: Em Gootee, MD
References:
https://pubmed.ncbi.nlm.nih.gov/21238663/
Patrus B, Nasr A, Langer JC, Gerstle JT. Intrasphincteric botulinum toxin decreases the rate of hospitalization for postoperative obstructive symptoms in children with Hirschsprung disease. J Pediatr Surg. 2011 Jan;46(1):184-7. doi: 10.1016/j.jpedsurg.2010.09.089. PMID: 21238663.
https://pubmed.ncbi.nlm.nih.gov/35690464/
Svetanoff WJ, Lim-Beutal IIP, Wood RJ, Levitt MA, Rentea RM. The utilization of botulinum toxin for Hirschsprung disease. Semin Pediatr Surg. 2022 Apr;31(2):151161. doi: 10.1016/j.sempedsurg.2022.151161. Epub 2022 Apr 8. PMID: 35690464.
https://pubmed.ncbi.nlm.nih.gov/33422904/
Rentea RM, Noel-MacDonnell JR, Bucher BT, Dorman MR, Lautz TB, Pruitt LCC, Oyetunji TA. Impact of Botulinum Toxin on Hirschsprung-Associated Enterocolitis After Primary Pull-Through. J Surg Res. 2021 May;261:95-104. doi: 10.1016/j.jss.2020.12.018. Epub 2021 Jan 7. PMID: 33422904.
https://pubmed.ncbi.nlm.nih.gov/37221126/
Encisco EM, Lim IIP, Velazco CS, Rosen NG, Garrison AP, Rymeski B, Frischer JS. Hirschsprung-Associated Enterocolitis at a Referral Institution: A Retrospective Review. J Pediatr Surg. 2023 Aug;58(8):1578-1581. doi: 10.1016/j.jpedsurg.2023.04.008. Epub 2023 Apr 20. PMID: 37221126.
https://pubmed.ncbi.nlm.nih.gov/33001257/
Svetanoff WJ, Dekonenko C, Osuchukwu O, Oyetunji TA, Aguayo P, Fraser JD, Juang D, Snyder CL, Hendrickson R, Peter SS, Rentea RM. Inpatient management of Hirschsprung’s associated enterocolitis treatment: the benefits of standardized care. Pediatr Surg Int. 2020 Dec;36(12):1413-1421. doi: 10.1007/s00383-020-04747-4. Epub 2020 Oct 1. PMID: 33001257.
Don’t forget to like and subscribe to see more entertaining medical educational videos!
See more lectures, articles, and more on the Stay Current app: https://www.globalcastmd.com/stay-current-app-download
